BACKGROUND: Antibody-mediated rejection (AMR) is a leading cause of morbidity and mortality after kidney transplantation. Early diagnosis and treatment of subclinical AMR based on the donor-specific antibody (DSA) testing may result in better outcomes. METHODS: We tested this hypothesis in 220 kidney transplant recipients who underwent an indication or DSA-based surveillance protocol biopsies between March 1, 2013 and December 31, 2016. Patients were divided into 3 groups: clinical AMR (n = 118), subclinical AMR (n = 25), or no rejection on protocol biopsy (controls; n = 77). RESULTS: Both clinical and subclinical AMR groups underwent similar treatment including plasmapheresis, pulse steroids, IVIG, and rituximab (P = ns). Mean follow-up after AMR was 29.5 ± 16.8 months. There were 2 (3%), 2 (8%), and 54 (46%) death-censored graft failures in the control, subclinical, and clinical AMR groups, respectively (P < 0.001). Graft outcomes were similar in the subclinical rejection and control groups. In adjusted Cox regression analysis, only clinical rejection (hazards ratio [HR], 4.31; 95% confidence interval [CI], 1.01-18.94; P = 0.05) and sum chronicity scores (HR, 1.16; 95% CI, 1.01-1.35; P = 0.03) were associated with increased risk of graft failure, while estimated glomerular filtration rate at time of biopsy (HR, 0.98; 95% CI, 0.96-0.99; P = 0.01) was associated with decreased risk of graft failure. CONCLUSIONS: Our study suggests that early diagnosis and treatment of subclinical AMR using DSA monitoring may improve outcomes after kidney transplantation.
BACKGROUND: Antibody-mediated rejection (AMR) is a leading cause of morbidity and mortality after kidney transplantation. Early diagnosis and treatment of subclinical AMR based on the donor-specific antibody (DSA) testing may result in better outcomes. METHODS: We tested this hypothesis in 220 kidney transplant recipients who underwent an indication or DSA-based surveillance protocol biopsies between March 1, 2013 and December 31, 2016. Patients were divided into 3 groups: clinical AMR (n = 118), subclinical AMR (n = 25), or no rejection on protocol biopsy (controls; n = 77). RESULTS: Both clinical and subclinical AMR groups underwent similar treatment including plasmapheresis, pulse steroids, IVIG, and rituximab (P = ns). Mean follow-up after AMR was 29.5 ± 16.8 months. There were 2 (3%), 2 (8%), and 54 (46%) death-censored graft failures in the control, subclinical, and clinical AMR groups, respectively (P < 0.001). Graft outcomes were similar in the subclinical rejection and control groups. In adjusted Cox regression analysis, only clinical rejection (hazards ratio [HR], 4.31; 95% confidence interval [CI], 1.01-18.94; P = 0.05) and sum chronicity scores (HR, 1.16; 95% CI, 1.01-1.35; P = 0.03) were associated with increased risk of graft failure, while estimated glomerular filtration rate at time of biopsy (HR, 0.98; 95% CI, 0.96-0.99; P = 0.01) was associated with decreased risk of graft failure. CONCLUSIONS: Our study suggests that early diagnosis and treatment of subclinical AMR using DSA monitoring may improve outcomes after kidney transplantation.
Authors: Michael Oellerich; Karen Sherwood; Paul Keown; Ekkehard Schütz; Julia Beck; Johannes Stegbauer; Lars Christian Rump; Philip D Walson Journal: Nat Rev Nephrol Date: 2021-05-24 Impact factor: 28.314
Authors: Natalie M Bath; Arjang Djamali; Sandesh Parajuli; Didier Mandelbrot; Glen Leverson; Luis Hidalgo; Thomas Ellis; Jillian L Descourouez; Margaret R Jorgenson; Dave Hager; Dixon B Kaufman; Robert R Redfield Journal: Kidney360 Date: 2020-10-01
Authors: Sookhyeon Park; Kexin Guo; Raymond L Heilman; Emilio D Poggio; David J Taber; Christopher L Marsh; Sunil M Kurian; Steve Kleiboeker; Juston Weems; John Holman; Lihui Zhao; Rohita Sinha; Susan Brietigam; Christabel Rebello; Michael M Abecassis; John J Friedewald Journal: Clin J Am Soc Nephrol Date: 2021-10 Impact factor: 10.614
Authors: Kenna R Degner; Nancy A Wilson; Shannon R Reese; Sandesh Parajuli; Fahad Aziz; Neetika Garg; Maha Mohamed; Tripti Singh; Didier A Mandelbrot; Sarah E Panzer; Robert R Redfield; Kristin Van Hyfte; Weixiong Zhong; Luis G Hidalgo; Arjang Djamali Journal: Kidney360 Date: 2020-05-28
Authors: Shannon R Reese; Nancy A Wilson; Yabing Huang; Lucille Ptak; Kenna R Degner; Ding Xiang; Robert R Redfield; Weixiong Zhong; Sarah E Panzer Journal: Transplantation Date: 2021-07-01 Impact factor: 5.385
Authors: John Peabody; Paul Billings; Czarlota Valdenor; Zach Demko; Solomon Moshkevich; David Paculdo; Mary Tran Journal: Int J Nephrol Date: 2019-05-13
Authors: Ali I Gardezi; Brenda Muth; Adil Ghaffar; Fahad Aziz; Neetika Garg; Maha Mohamed; David Foley; Dixon Kaufman; Arjang Djamali; Didier Mandelbrot; Sandesh Parajuli Journal: Kidney Int Rep Date: 2021-04-17